[go: up one dir, main page]

JP2001513796A - （ｅ）−４，６−ジクロロ−３−（２−オキソ−１−フェニルピロリジン−３−イリデンメチル）−１ｈ−インドール−２−カルボン酸の結晶性ナトリウム塩水和物 - Google Patents

（ｅ）−４，６−ジクロロ−３−（２−オキソ−１−フェニルピロリジン−３−イリデンメチル）−１ｈ−インドール−２−カルボン酸の結晶性ナトリウム塩水和物

Info

Publication number
JP2001513796A
JP2001513796A JP53813598A JP53813598A JP2001513796A JP 2001513796 A JP2001513796 A JP 2001513796A JP 53813598 A JP53813598 A JP 53813598A JP 53813598 A JP53813598 A JP 53813598A JP 2001513796 A JP2001513796 A JP 2001513796A
Authority
JP
Japan
Prior art keywords
sodium salt
compound
oxo
crystalline hydrate
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53813598A
Other languages
English (en)
Japanese (ja)
Inventor
ツァデオ、チマロスティ
パオロ、マラーニ
Original Assignee
グラクソ、ウェルカム、ソシエタ、ペル、アツィオーニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソ、ウェルカム、ソシエタ、ペル、アツィオーニ filed Critical グラクソ、ウェルカム、ソシエタ、ペル、アツィオーニ
Publication of JP2001513796A publication Critical patent/JP2001513796A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP53813598A 1997-03-05 1998-03-03 （ｅ）−４，６−ジクロロ−３−（２−オキソ−１−フェニルピロリジン−３−イリデンメチル）−１ｈ−インドール−２−カルボン酸の結晶性ナトリウム塩水和物 Pending JP2001513796A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9704498.6 1997-03-05
GBGB9704498.6A GB9704498D0 (en) 1997-03-05 1997-03-05 Chemical compound
PCT/EP1998/001146 WO1998039327A1 (en) 1997-03-05 1998-03-03 Crystalline hydrated sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1h-indole-2-carboxylic acid

Publications (1)

Publication Number Publication Date
JP2001513796A true JP2001513796A (ja) 2001-09-04

Family

ID=10808697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53813598A Pending JP2001513796A (ja) 1997-03-05 1998-03-03 （ｅ）−４，６−ジクロロ−３−（２−オキソ−１−フェニルピロリジン−３−イリデンメチル）−１ｈ−インドール−２−カルボン酸の結晶性ナトリウム塩水和物

Country Status (29)

Country Link
EP (1) EP0966463A1 (is)
JP (1) JP2001513796A (is)
KR (1) KR20000075907A (is)
CN (1) CN1249750A (is)
AP (1) AP9901637A0 (is)
AR (1) AR011178A1 (is)
AU (1) AU6825198A (is)
BG (1) BG103779A (is)
BR (1) BR9808305A (is)
CA (1) CA2282851A1 (is)
CO (1) CO4940415A1 (is)
EA (1) EA199900710A1 (is)
EE (1) EE9900387A (is)
GB (1) GB9704498D0 (is)
HR (1) HRP980114A2 (is)
HU (1) HUP0002109A2 (is)
ID (1) ID24207A (is)
IL (1) IL131489A0 (is)
IS (1) IS5166A (is)
NO (1) NO994303L (is)
NZ (1) NZ337315A (is)
OA (1) OA11154A (is)
PE (1) PE51399A1 (is)
PL (1) PL335652A1 (is)
SK (1) SK119699A3 (is)
TR (1) TR199902117T2 (is)
WO (1) WO1998039327A1 (is)
YU (1) YU43499A (is)
ZA (1) ZA981791B (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704499D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Method of manufacture
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX393950B (es) 2017-06-12 2025-03-24 Glytech Llc Composicion y metodo para el tratamiento de la depresion y psicosis en humanos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
EP0966463A1 (en) 1999-12-29
IL131489A0 (en) 2001-01-28
KR20000075907A (ko) 2000-12-26
ID24207A (id) 2000-07-13
YU43499A (sh) 2000-12-28
IS5166A (is) 1999-08-27
PE51399A1 (es) 1999-06-07
AU6825198A (en) 1998-09-22
CO4940415A1 (es) 2000-07-24
CN1249750A (zh) 2000-04-05
SK119699A3 (en) 2000-05-16
NO994303L (no) 1999-11-03
PL335652A1 (en) 2000-05-08
EA199900710A1 (ru) 2000-04-24
HUP0002109A2 (hu) 2001-04-28
BR9808305A (pt) 2000-05-16
EE9900387A (et) 2000-04-17
NO994303D0 (no) 1999-09-03
ZA981791B (en) 1999-09-03
OA11154A (en) 2003-04-16
AR011178A1 (es) 2000-08-02
NZ337315A (en) 2001-02-23
AP9901637A0 (en) 1999-09-30
TR199902117T2 (xx) 2000-03-21
WO1998039327A1 (en) 1998-09-11
GB9704498D0 (en) 1997-04-23
BG103779A (en) 2000-06-30
CA2282851A1 (en) 1998-09-11
HRP980114A2 (en) 1998-12-31

Similar Documents

Publication Publication Date Title
JPH07505407A (ja) インドール誘導体
TWI519532B (zh) （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
JP2000505450A (ja) キノロン類およびこれらの治療的使用
EP2631234A1 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
JP2001513796A (ja) （ｅ）−４，６−ジクロロ−３−（２−オキソ−１−フェニルピロリジン−３−イリデンメチル）−１ｈ−インドール−２−カルボン酸の結晶性ナトリウム塩水和物
JP2002532470A (ja) パロキセチンマレイン酸塩の製法
JP2001518901A (ja) キノリン−２−カルボン酸誘導体およびその興奮性アミノ酸拮抗薬としての使用
CA2393303C (en) Meglumine salt of a specific quinolinecarboxylic acid compound
CN1214029C (zh) 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物
JP2002528541A (ja) Ｔｎｆおよびｐｄｅ−ｉｖ阻害活性を有する複素環式化合物のｎ−オキシド
JP2023506025A (ja) レンボレキサントの固体形態
WO2002008229A1 (fr) DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO [4,5-β] INDOLE-1-CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
CZ314799A3 (cs) Krystalická hydratovaná sodná sůl kyseliny (E)-4,6-dichlor-3-(2-oxo-l-fenylpyrrolidin-3- ylidenmethyl)-lH-indol-2-karboxylové
JPH10503532A (ja) レソピトロン二塩酸塩の新規多形およびその水和形その製造方法およびそれを含有する組成物
HK1156598B (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
HK1156598A1 (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
HK1189888A (en) Intermediates for preparing indole benzylamine compound